A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

The purpose of this research study is to determine whether the study drug, EDP1815, is safe and effective in the treatment of atopic dermatitis compared with placebo. The study will look at different doses of the study drug, and whether there are differences when the drug is given once daily or twice daily.

Key facts

Study ID

NCT05121480

Run by

Evelo Biosciences, Inc.

People needed

421

Starts

2022-01-31

Expected to finish

2023-03-28

Last updated by the study team

2023-08-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provide written informed consent.
• Must meet age criteria.
• Must have a diagnosis of atopic dermatitis (AD)for at least 6 months.
• Must have severity of atopic dermatitis meeting the below criteria at both Screening and Day 1:
• An IGA of 2, 3 or 4 on the vIGA scale, and;
• A BSA of ≥5%, and;
• An EASI score of ≥6.
• Must agree to use emollients.
• Must meet contraception requirements.

You may not qualify if…

• Have been in a clinical trial for EDP1815 prior to signing of ICF.
• Use of phototherapy or tanning beds; systemic medications/treatments that could affect AD or its symptoms including immunosuppressive therapy (e.g., oral or injectable corticosteroids, methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, JAK inhibitors, tacrolimus, and/or leukotriene inhibitor) within 4 weeks of randomization.
• Treatment with topical agents that could affect atopic dermatitis, including topical corticosteroids, topical calcineurin inhibitors (e.g., tacrolimus or pimecrolimus), or topical PDE-4 inhibitor (e.g., crisaborole) within 14 days prior to randomization.
• Clinically significant abnormalities in screening laboratory values that in the opinion of the Investigator would make a participant unsuitable for inclusion in the study. One retest is permitted within the 28-day screening window.
• Hypersensitivity to P histicola or to any of the excipients.
• Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator.
• Have any other conditions, which, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study.

Where it is running

• AUS-104 — Kogarah, Australia
• AUS-101 — Melbourne, Australia
• AUS-106 — Woolloongabba, Australia
• BGR-105 — Pleven, Bulgaria
• USA-131 — Birmingham, Alabama, United States
• USA-112 — Fountain Valley, California, United States
• USA-123 — Fremont, California, United States
• USA-114 — Newport Beach, California, United States
• USA-101 — Fort Lauderdale, Florida, United States
• USA-124 — Jacksonville, Florida, United States
• USA-108 — Miami, Florida, United States
• USA-120 — Miami, Florida, United States
• USA-105 — Miramar, Florida, United States
• USA-102 — Orlando, Florida, United States
• USA-115 — Sweetwater, Florida, United States
• USA-126 — Tampa, Florida, United States
• USA-106 — Tampa, Florida, United States
• USA-118 — Sandy Springs, Georgia, United States
• USA-111 — Clarksville, Indiana, United States
• USA-116 — Louisville, Kentucky, United States
• USA-119 — Baton Rouge, Louisiana, United States
• USA-109 — Metairie, Louisiana, United States
• USA-125 — Silver Spring, Maryland, United States
• USA-130 — Ann Arbor, Michigan, United States
• AUS-102 — Carlton, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.